Standout Papers
- Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis (2018)
- SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials (2022)
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis (2014)
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials (2020)
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction (2015)
- Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone (2015)
- Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients (2015)
- Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure (2018)
- Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum (2018)
- Sex Differences in Blood Pressure Trajectories Over the Life Course (2020)
- Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (2019)
- Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the
DELIVER trial (2021) - Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19 (2021)
- Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria (2023)
- Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis (2024)
- Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial (2025)
Immediate Impact
1 by Nobel laureates 68 standout
Citing Papers
From geroscience to precision geromedicine: Understanding and managing aging
2025 Standout
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
2024 Standout
Works of Brian Claggett being referenced
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
2023 Standout
Adiposity, Body Composition and Ventricular–Arterial Stiffness in the Elderly: The Atherosclerosis Risk in Communities Study
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Brian Claggett | 11841 | 3761 | 2989 | 536 | 18.4k | |
| Eric L. Michelson | 17113 | 3137 | 2245 | 191 | 20.2k | |
| Hans L. Hillege | 15885 | 2368 | 4924 | 380 | 26.5k | |
| Susan R. Heckbert | 9711 | 3742 | 1686 | 474 | 21.0k | |
| Muthiah Vaduganathan | 11772 | 3741 | 2232 | 609 | 17.9k | |
| Akshay S. Desai | 16262 | 4472 | 3747 | 379 | 20.2k | |
| Inder S. Anand | 17182 | 2573 | 2937 | 412 | 22.5k | |
| G. Michael Felker | 16705 | 1745 | 4104 | 412 | 23.1k | |
| Robert J. Mentz | 9487 | 4051 | 2247 | 563 | 14.9k | |
| Raymond R. Townsend | 14160 | 4329 | 2948 | 427 | 24.6k | |
| Gianni Tognoni | 11391 | 2748 | 3652 | 255 | 23.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...